Clinical trial
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following…
NCT00250276 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00250276 |
|---|---|
| Title | Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. |
| Official title | Assess Lot-to-lot Consistency of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Following Manufacturing Adjustments Administered Intramuscularly According to a 0,1,6-mth Schedule in Healthy Female Subjects (18-25 y) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus, Papillomavirus Vaccines |
| Intervention type | Biological |
| Interventions | Cervarix™ |
| Enrollment | 798 |
| Start date | Oct 28, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Nov 8, 2005 |
| Last update posted | Jan 2, 2020 |
| Countries | Denmark, Lithuania, Poland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: